JMP Securities Reaffirms Market Outperform Rating for Ocular Therapeutix
Analyst Jonathan Wolleben from JMP Securities has reaffirmed Ocular Therapeutix (NASDAQ: OCUL) with a Market Outperform rating and a $24 ...
Tag: OCUL
Analyst Reiterates Positive Outlook on Ocular Therapeutix with Increased Price Target
Piper Sandler analyst Joseph Catanzaro has reiterated his positive outlook on Ocular Therapeutix (NASDAQ: OCUL) by maintaining an Overweight rating ...
Don't Miss It
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
